ADx NeuroSciences and Alamar Biosciences announce partnership to provide customized blood-based biomarker assay solutions to accelerate biopharma clinical development
We’re proud to announce our collaboration with Alamar Biosciences, Inc.!…
ADx NeuroSciences
Always up-to-date of the latest developments
ADx and Fujirebio Join Forces with Biogen and Beckman Coulter to Advance Alzheimer’s Diagnostics
ADx and Fujirebio Join Forces with Biogen and Beckman Coulter to Advance Alzheimer’s Diagnostics
ADx, together with Fujirebio, is excited to announce a new…
ADx will join AAIC 2024
ADx will join AAIC 2024
We will be present at the 2024 edition of AAIC…
ADx will attend AD/PD 2024
ADx will attend AD/PD 2024
ADx is excited to attend AD/PD 2024 this year in…
Scientific articles in 2024
Scientific articles in 2024
In 2024, ADx remains committed to fostering collaborative efforts with…
We officially moved into our new offices!
We officially moved into our new offices!
More than a year ago our company was welcomed into…
ADx will attend AAIC2023
ADx will attend AAIC2023
ADx is excited to attend AAIC2023 this year in Amsterdam,…
ADx is attending CSF society 2024
ADx is attending CSF society 2024
Come and meet us at the CSF Society Conference in…
Scientific articles in 2023
Scientific articles in 2023
In 2023 ADx will continue to collaborate with its research…
ADx will attend the clinical workshop CURE-ND in Paris
ADx will attend the clinical workshop CURE-ND in Paris
On friday February 3rd, ADx NeuroSciences will attend a workshop…
Fujirebio acquires ADx NeuroSciences and confirms its intentions to bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry
Fujirebio acquires ADx NeuroSciences and confirms its intentions to bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry
Gent, Belgium and Tokyo, Japan, June 23, 2022 – H.U.…
Scientific articles in 2022
Scientific articles in 2022
In 2022 ADx will continue to collaborate with its research…
ADx NeuroSciences’ review of 2021
ADx NeuroSciences’ review of 2021
2021 was a remarkable year for ADx. Check out our…
Scientific articles in 2021
Scientific articles in 2021
In 2021, ADx NeuroSciences' collaborators worked intensively on groundbreaking scientific…
Scientific articles in 2020
Scientific articles in 2020
In 2020, ADx NeuroSciences' collaborators have been intensively participating in…
ADx will be present at the upcoming virtual AAIC 2020
ADx will be present at the upcoming virtual AAIC 2020
Discover the new findings in blood and synaptic biomarkers at…
Cancellation ADx Neuro Biomarker Conference
Cancellation ADx Neuro Biomarker Conference
We regret to announce that the ADx Neuro Biomarker Conference…
ADx presents at ADPD results on VAMP2, a new synaptic biomarker showing significant changes in very early pre-clinical disease state.
ADx presents at ADPD results on VAMP2, a new synaptic biomarker showing significant changes in very early pre-clinical disease state.
While the classical fluid markers, tau and amyloid, accord well…
Scientific articles in 2019
Scientific articles in 2019
In 2019, ADx NeuroSciences' collaborators were intensively participating in groundbreaking…
Present at CTAD 2019
Present at CTAD 2019
ADx NeuroSciences will be present at CTAD. You can reach…
ADx receives funding from Bill Gates for developing blood biomarkers
ADx receives funding from Bill Gates for developing blood biomarkers
Together with Douglas Galasko, M.D. University of California at San…
Scientific articles in 2018
Scientific articles in 2018
ADx NeuroSciences is an R&D company and its people are…